ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Sinocelltech Group and Merck side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Sinocelltech GroupMerck
studies on the registry822,455
open to participants now33146
phase 3 studies under way12112
reach primary completion within a year1059
programswith a study of their own in two years1384

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseSinocelltech GroupMerck
Phase 1

Sinocelltech Group: 2 of its 13 programs at phase 1

  1. SCTA02Aphase 1
  2. SCTB10phase 1
15%

Merck: 27 of its 84 programs at phase 1

  1. MK4646phase 1
  2. F-2phase 1
  3. MK-7602phase 1
  4. V118Cphase 1
  5. MK-4716phase 1

and 22 more — sign in to see them all

32%
Phase 2

Sinocelltech Group: 6 of its 13 programs at phase 2

  1. SCT650Cphase 2
  2. SCTB39-1phase 2
  3. SCTB39Gphase 2
  4. Recombinant Herpes Zoster Vaccine (SCTV04C) Low-Dosephase 2
  5. SCTT11phase 2

and 1 more — sign in to see them all

46%
23%
Phase 3

Sinocelltech Group: 4 of its 13 programs at phase 3

  1. SCTB41phase 3
  2. Anti-CD38 Monoclonal Antibody SCTC21Cphase 3
  3. SCTB35phase 3
  4. Anti-PD-1/Anti-VEGF Bispecific Antibody SCTB14phase 3
31%

Merck: 35 of its 84 programs at phase 3

  1. sacituzumab tirumotecanphase 3
  2. belzutifanphase 3
  3. tulisokibartphase 3
  4. ifinatamab deruxtecanphase 3
  5. intismeran autogenephase 3

and 30 more — sign in to see them all

42%
Approved, new studies

Sinocelltech Group: 1 of its 13 programs at approved, new studies

  1. omfiloctocog alfaapproved, new study
8%

Merck: 3 of its 84 programs at approved, new studies

  1. pembrolizumabapproved, new study
  2. sotaterceptapproved, new study
  3. Metforminapproved, new study
4%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Sinocelltech Group8 readouts · 1 phase 3····

Sinocelltech Group, Mar ’27: 1 program whose next study reaches primary completion

  1. SCT650Cphase 2 · Mar 12 · NCT07244510

Sinocelltech Group, Apr ’27: 2 programs whose next study reaches primary completion

  1. Anti-CD38 Monoclonal Antibody SCTC21Cphase 3 · Apr 0 · NCT07538154
  2. SCTB41phase 3 · Apr 30 · NCT06600022

Sinocelltech Group, May ’27: 1 program whose next study reaches primary completion

  1. SCTB35phase 3 · May 0 · NCT06841042
·

Sinocelltech Group, Jul ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. Anti-PD-1/Anti-VEGF Bispecific Antibody SCTB14phase 3 · Jul 0 · NCT07362459
  2. SCTV02phase 2 · Jul 30 · NCT06754605
·

Sinocelltech Group, Sep ’27: 2 programs whose next study reaches primary completion

  1. SCTA02Aphase 1 · Sep 0 · NCT07903831
  2. SCTB39Gphase 2 · Sep 26 · NCT07077252
·
Merck25 readouts · 6 phase 3

Merck, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. pembrolizumabapproved, new study · Nov 20 · NCT04634877

Merck, Dec ’26: 3 programs whose next study reaches primary completion

  1. enlicitide chloridephase 3 · Dec 14 · NCT07776665
  2. F-2phase 1 · Dec 15 · NCT07748351
  3. efitazanamivir alfaphase 3 · Dec 31 · NCT07300085

Merck, Jan ’27: 3 programs whose next study reaches primary completion, 2 in phase 3

  1. remigromigphase 3 · Jan 11 · NCT06957080
  2. Human Papillomavirus Recombinant Vaccine nonavalentphase 3 · Jan 15 · NCT04199689
  3. alimatravirphase 3 · Jan 19 · NCT07600775

Merck, Feb ’27: 4 programs whose next study reaches primary completion

  1. nemtabrutinibphase 3 · Feb 1 · NCT07734610
  2. MK-6916phase 2 · Feb 9 · NCT07862621
  3. tulisokibartphase 3 · Feb 17 · NCT07486960
  4. belzutifanphase 3 · Feb 26 · NCT03634540

Merck, Mar ’27: 1 program whose next study reaches primary completion

  1. ensifentrinephase 3 · Mar 1 · NCT05270525

Merck, Apr ’27: 3 programs whose next study reaches primary completion

  1. MK-7602phase 1 · Apr 5 · NCT07919028
  2. pyronaridinephase 1 · Apr 5 · NCT07919028
  3. intismeran autogenephase 3 · Apr 23 · NCT06305767

Merck, May ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. sacituzumab tirumotecanphase 3 · May 10 · NCT06074588

Merck, Jun ’27: 2 programs whose next study reaches primary completion

  1. ifinatamab deruxtecanphase 3 · Jun 12 · NCT07405151
  2. ulonivirinephase 3 · Jun 29 · NCT05093972

Merck, Jul ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. V118Ephase 1 · Jul 6 · NCT07168915
  2. bomedemstatphase 3 · Jul 14 · NCT06079879
  3. Anti-nectin-4 Antibody-drug Conjugate MK-3120phase 2 · Jul 30 · NCT07222488

Merck, Aug ’27: 1 program whose next study reaches primary completion

  1. islatravirphase 3 · Aug 10 · NCT06891066

Merck, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. zilovertamab vedotinphase 3 · Sep 24 · NCT05139017

Merck, Oct ’27: 2 programs whose next study reaches primary completion

  1. HRS-5346phase 2 · Oct 12 · NCT07614984
  2. MK-8690phase 2 · Oct 19 · NCT07895524
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 23, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Sinocelltech Group

New programs 2

  • SCTA02Aphase 1 · first study · Oct 16 · Hepatitis B, Chronic
  • SCTB10phase 1 · first study · Sep 17

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Merck

New programs 7

  • V951Aphase 1 · first study · Nov 10
  • pyronaridinephase 1 · first study · Oct 30 · Malaria, Falciparum
  • MK-2750phase 2 · first study · Oct 9 · Neoplasms
  • MK-6255phase 1 · first study · Oct 6 · Ovarian Neoplasms
  • V175phase 1 · first study · Sep 28
  • V175Aphase 1 · first study · Sep 28
  • Merck: new programs in 90 days

    1. V951Aphase 1 · first study · Nov 10
    2. pyronaridinephase 1 · first study · Oct 30
    3. MK-2750phase 2 · first study · Oct 9
    4. MK-6255phase 1 · first study · Oct 6
    5. V175phase 1 · first study · Sep 28

    and 2 more — sign in to see them all

Reached a new phase 2

  • gocatamigphase 3 · Oct 26 · Small Cell Lung Carcinoma
  • MK-6916phase 2 · Oct 2 · Renal Insufficiency

Study stopped 4

Primary completion later 6

Where they overlap

Conditions where at least two of them have programs: 7 in all. A program counts in each condition its studies name most.

ConditionSinocelltech GroupMerck
Carcinoma, Non-Small-Cell Lungboth · compare here

Sinocelltech Group in Carcinoma, Non-Small-Cell Lung: 2 programs

  1. SCTB41phase 3
  2. Anti-PD-1/Anti-VEGF Bispecific Antibody SCTB14phase 3

Their studies: Sinocelltech Group’s studies of Carcinoma, Non-Small-Cell Lung in search

Merck in Carcinoma, Non-Small-Cell Lung: 10 programs

  1. sacituzumab tirumotecanphase 3
  2. ifinatamab deruxtecanphase 3
  3. intismeran autogenephase 3
  4. patritumab deruxtecanphase 3
  5. calderasibphase 3

and 5 more — sign in to see them all

Their studies: Merck’s studies of Carcinoma, Non-Small-Cell Lung in search

Lupus Erythematosus, Systemicboth · compare here

Sinocelltech Group in Lupus Erythematosus, Systemic: 2 programs

  1. Anti-CD38 Monoclonal Antibody SCTC21Cphase 3
  2. SCTB35phase 3

Their studies: Sinocelltech Group’s studies of Lupus Erythematosus, Systemic in search

Merck in Lupus Erythematosus, Systemic: 1 program

  1. MK-6194phase 2

Their studies: Merck’s studies of Lupus Erythematosus, Systemic in search

Lymphoma, Non-Hodgkinboth · compare here

Sinocelltech Group in Lymphoma, Non-Hodgkin: 2 programs

  1. SCTB41phase 3
  2. SCTB35phase 3

Their studies: Sinocelltech Group’s studies of Lymphoma, Non-Hodgkin in search

Merck in Lymphoma, Non-Hodgkin: 1 program

  1. Anti-CD19/CD3 Bispecific Antibody MK-1045phase 3

Their studies: Merck’s studies of Lymphoma, Non-Hodgkin in search

Axial Spondyloarthritisboth · compare here

Sinocelltech Group in Axial Spondyloarthritis: 1 program

  1. SCT650Cphase 2

Their studies: Sinocelltech Group’s studies of Axial Spondyloarthritis in search

Merck in Axial Spondyloarthritis: 1 program

  1. tulisokibartphase 3

Their studies: Merck’s studies of Axial Spondyloarthritis in search

Hematologic Neoplasmsboth · compare here

Sinocelltech Group in Hematologic Neoplasms: 1 program

  1. Anti-CD38 Monoclonal Antibody SCTC21Cphase 3

Their studies: Sinocelltech Group’s studies of Hematologic Neoplasms in search

Merck in Hematologic Neoplasms: 1 program

  1. nemtabrutinibphase 3

Their studies: Merck’s studies of Hematologic Neoplasms in search

Lymphoma, Follicularboth · compare here

Sinocelltech Group in Lymphoma, Follicular: 1 program

  1. SCTB35phase 3

Their studies: Sinocelltech Group’s studies of Lymphoma, Follicular in search

Merck in Lymphoma, Follicular: 1 program

  1. Anti-CD19/CD3 Bispecific Antibody MK-1045phase 3

Their studies: Merck’s studies of Lymphoma, Follicular in search

Multiple Myelomaboth · compare here

Sinocelltech Group in Multiple Myeloma: 1 program

  1. Anti-CD38 Monoclonal Antibody SCTC21Cphase 3

Their studies: Sinocelltech Group’s studies of Multiple Myeloma in search

Merck in Multiple Myeloma: 1 program

  1. sotaterceptapproved, new study

Their studies: Merck’s studies of Multiple Myeloma in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Sinocelltech Group 5 of 13 · Merck 40 of 84 programs (17 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.